ArticleHepatobiliary surgery and nutrition2025
Performance of major liver resection for gallbladder cancer-a western retrospective single center cohort study.
Article in Hepatobiliary surgery and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gallbladder cancer (GBCa) is a rare disease in western countries and surgery remains the state of art, given the tumor is technically resectable. However, data for major liver resection in patients with advanced GBCa is scarce. Objective of this study was to analyze survival outcome measures of patients undergoing major liver resection for GBCa. Methods: We conducted a single center retrospective cohort study in a high volume hepato-pancreato-biliary (HPB) center screening all patients with gallbladder cancer (GBCa) being treated between 2008-2023. Inclusion criteria were met when resection [major hepatectomy (MaH); minor hepatectomy (MiH)] or palliative chemotherapy (either after surgical exploration Results: In total, 167 patients met the inclusion criteria, with 80 patients undergoing resection (MaH, n=20; MiH, n=60) and 87 patients undergoing palliative chemotherapy (n=68 after surgical exploration, n=19 primary palliative chemotherapy). The median survival for patients receiving a MaH or MiH were 11.96 months [95% confidence interval (CI): 1.11-22.81] and 25.1 months (95% CI: 19.37-30.85), respectively. MiH was associated with statistically significant improved survival compared to every other group (MiH Conclusions: MiH, if applicable, is associated with improved survival in GBCa, whereas only few patients benefited from major hepatectomies. This is, however, not attributable to the surgical technique, but rather to the advanced tumor necessitating major and/or extended resections. New neoadjuvant chemotherapy concepts are urgently needed to reduce preoperative tumor burden and improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.